Medexus Pharmaceuticals Inc $MDP.TO $MEDXF - Deep Dive Research Report # 22
Balancing Growth & Uncertainty: GRAFAPEX Launch!!
Medexus Pharmaceuticals:
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company with a strong North American presence, focusing on therapeutic areas such as hematology, oncology, allergy, dermatology, and rheumatology.
Overview:
Medexus Pharmaceuticals Inc. was formed in September 2018 through the merger of three companies:
Pediapharm Inc. (est. 2008, Canada): Specialized in pediatric healthcare with products like NYDA, Relaxa, and Rupall.
Medexus Inc. (est. 2000): Focused on rheumatology, neurology, and autoimmune diseases with key products such as Metoject and Oralvisc.
Medac Pharma (est. 2012, USA): A subsidiary of medac GmbH, specializing in rheumatology, hematology, and oncology, with products like Rasuvo and treosulfan.
The merger strengthened Medexus Pharmaceuticals’ commercial platform, enabling it to better address unmet medical needs with a portfolio of specialty pharmaceutical products.
Product Portfolio:
Hematology-oncology is a branch of medicine that focuses on blood-related cancers and blood disorders. "Hematology" deals with diseases related to the blood, such as anemia or clotting problems. "Oncology" focuses on cancers, so hematology-oncology covers cancers of the blood like leukemia, lymphoma, and myeloma.
Dermatology is the study of skin and its related conditions. Dermatologists treat issues like acne, eczema, psoriasis, skin infections, rashes, and even skin cancer. Essentially, dermatology deals with anything that affects the skin, hair, and nails. Allergy/dermatology often overlaps when someone has allergic reactions that affect their skin, leading to conditions like hives, eczema, or contact dermatitis.
Rheumatology is the study and treatment of conditions that affect the joints, muscles, and bones, often causing pain or inflammation. This includes diseases like arthritis, lupus, and gout, which can lead to chronic pain and swelling in the joints.
Their product portfolio includes the following key products:
Medexus’s leading products in the hematology-oncology product group include:
Gleolan (for Brain Tumor Surgery)
Indication: Gleolan (aminolevulinic acid hydrochloride) is used as an intraoperative imaging agent to assist neurosurgeons in visualizing and resecting gliomas, a type of brain tumor. In other words, it’s a special imaging dye that helps surgeons see brain tumors more clearly during surgery. The dye makes tumor cells glow under a special light, so doctors can remove them more accurately.
Market Presence: Medexus has been commercializing Gleolan in the United States since March 2022
Competitors: While Gleolan is a unique agent for fluorescence-guided surgery in glioma treatment, alternative intraoperative imaging technologies, such as intraoperative MRI and ultrasound, may serve as indirect competitors. Not many direct competitors, but other imaging methods like MRI and ultrasound are used
Average Sales Price: The cost of Gleolan can vary depending on factors such as the pharmacy and location. According to available data, the price for Gleolan (30 mg/mL oral powder for reconstitution) ranges from approximately $2,920.97 to $3,345.87 per unit.
IXINITY (for Hemophilia B)